Literature DB >> 35210786

Kynurenine Pathway in Chronic Kidney Disease: What's Old, What's New, and What's Next?

Adrian Mor1, Bartlomiej Kalaska1, Dariusz Pawlak1.   

Abstract

Impaired kidney function and increased inflammatory process occurring in the course of Chronic Kidney Disease (CKD) contribute to the development of complex amino-acid alterations. The essential amino-acid tryptophan (TRP) undergoes extensive metabolism along several pathways, resulting in the production of many biologically active compounds. The results of many studies have shown that its metabolism via the kynurenine pathway is potently increased in the course of CKD. Metabolites of this pathway exhibit differential, sometimes opposite, roles in several biological processes. Their accumulation in the course of CKD may induce oxidative cell damage which stimulates inflammatory processes. They can also modulate the activity of numerous cellular signaling pathways through activation of the aryl hydrocarbon receptor, leading to the disruption of homeostasis of various organs. As a result, they can contribute to the development of the systemic disorders accompanying the course of chronic renal failure. This review gathers and systematizes reports concerning the knowledge connecting the kynurenine pathway metabolites to systemic disorders accompanying the development of CKD.
© The Author(s) 2020.

Entities:  

Keywords:  Tryptophan; chronic kidney disease; kynurenine; mineral and bone disorders; neurological disorders; thrombosis

Year:  2020        PMID: 35210786      PMCID: PMC8862190          DOI: 10.1177/1178646920954882

Source DB:  PubMed          Journal:  Int J Tryptophan Res        ISSN: 1178-6469


  206 in total

1.  Xanthurenic acid, an abnormal metabolite of tryptophan and the diabetic symptoms caused in albino rats by its production.

Authors:  Y KOTAKE
Journal:  J Vitaminol (Kyoto)       Date:  1955-02-10

2.  The role of group I and group II metabotropic glutamate receptors in modulation of striatal NMDA and quinolinic acid toxicity.

Authors:  L R Orlando; S A Alsdorf; J B Penney; A B Young
Journal:  Exp Neurol       Date:  2001-01       Impact factor: 5.330

3.  Enhanced neuronal damage by co-administration of quinolinic acid and free radicals, and protection by adenosine A2A receptor antagonists.

Authors:  W M H Behan; T W Stone
Journal:  Br J Pharmacol       Date:  2002-03       Impact factor: 8.739

4.  Selective inhibition of IDO1, D-1-methyl-tryptophan (D-1MT), effectively increased EpCAM/CD3-bispecific BiTE antibody MT110 efficacy against IDO1hibreast cancer via enhancing immune cells activity.

Authors:  Ri Hong; Yuhai Zhou; Xiujuan Tian; Lijuan Wang; Xiaoyun Wu
Journal:  Int Immunopharmacol       Date:  2017-11-09       Impact factor: 4.932

5.  The tryptophan metabolite 3-hydroxyanthranilic acid plays anti-inflammatory and neuroprotective roles during inflammation: role of hemeoxygenase-1.

Authors:  Daniela Krause; Hyeon-Sook Suh; Leonid Tarassishin; Qiao Ling Cui; Bryce A Durafourt; Namjong Choi; Avital Bauman; Melissa Cosenza-Nashat; Jack P Antel; Meng-Liang Zhao; Sunhee C Lee
Journal:  Am J Pathol       Date:  2011-09       Impact factor: 4.307

6.  The uremic toxin 3-indoxyl sulfate is a potent endogenous agonist for the human aryl hydrocarbon receptor.

Authors:  Jennifer C Schroeder; Brett C Dinatale; Iain A Murray; Colin A Flaveny; Qiang Liu; Elizabeth M Laurenzana; Jyh Ming Lin; Stephen C Strom; Curtis J Omiecinski; Shantu Amin; Gary H Perdew
Journal:  Biochemistry       Date:  2010-01-19       Impact factor: 3.162

7.  Induction of indolamine 2,3-dioxygenase and kynurenine 3-monooxygenase in rat brain following a systemic inflammatory challenge: a role for IFN-gamma?

Authors:  Thomas J Connor; Neasa Starr; Joan B O'Sullivan; Andrew Harkin
Journal:  Neurosci Lett       Date:  2008-06-07       Impact factor: 3.046

8.  Increased levels of 3-hydroxykynurenine in different brain regions of rats with chronic renal insufficiency.

Authors:  Joanna Topczewska-Bruns; Dariusz Pawlak; Ewa Chabielska; Anna Tankiewicz; Wlodzimierz Buczko
Journal:  Brain Res Bull       Date:  2002-08-15       Impact factor: 4.077

9.  Kynurenine, quinolinic acid--the new factors linked to carotid atherosclerosis in patients with end-stage renal disease.

Authors:  Krystyna Pawlak; Szymon Brzosko; Michal Mysliwiec; Dariusz Pawlak
Journal:  Atherosclerosis       Date:  2008-10-14       Impact factor: 5.162

10.  Indoxyl sulfate - the uremic toxin linking hemostatic system disturbances with the prevalence of cardiovascular disease in patients with chronic kidney disease.

Authors:  Tomasz W Kamiński; Krystyna Pawlak; Małgorzata Karbowska; Michał Myśliwiec; Dariusz Pawlak
Journal:  BMC Nephrol       Date:  2017-01-25       Impact factor: 2.388

View more
  6 in total

1.  Differential Distribution of Tryptophan-Metabolites in Fetal and Maternal Circulations During Normotensive and Preeclamptic Pregnancies.

Authors:  Ying-Jie Zhao; Chi Zhou; Ying-Ying Wei; Hui-Hui Li; Wei Lei; Derek S Boeldt; Kai Wang; Jing Zheng
Journal:  Reprod Sci       Date:  2021-10-07       Impact factor: 3.060

Review 2.  An Emerging Cross-Species Marker for Organismal Health: Tryptophan-Kynurenine Pathway.

Authors:  Laiba Jamshed; Amrita Debnath; Shanza Jamshed; Jade V Wish; Jason C Raine; Gregg T Tomy; Philippe J Thomas; Alison C Holloway
Journal:  Int J Mol Sci       Date:  2022-06-04       Impact factor: 6.208

3.  Plasma Kynurenine: A Promising Marker for the Assessment of Renal Functions.

Authors:  Fatimah Brekdar; Muhammed Imad Khayat; Afraa Zrieki
Journal:  Int J Tryptophan Res       Date:  2022-05-26

4.  Admission Urinary and Serum Metabolites Predict Renal Outcomes in Hospitalized Patients With Cirrhosis.

Authors:  Jasmohan S Bajaj; Guadalupe Garcia-Tsao; K Rajender Reddy; Jacqueline G O'Leary; Hugo E Vargas; Jennifer C Lai; Patrick S Kamath; Puneeta Tandon; Ram M Subramanian; Paul Thuluvath; Andrew Fagan; Tejasav Sehrawat; Randolph de la Rosa Rodriguez; Leroy R Thacker; Florence Wong
Journal:  Hepatology       Date:  2021-07-08       Impact factor: 17.298

5.  Acceptability and feasibility of fecal microBIOME and serum metabolite sample collection in people with end-stage kidney disease and pain being treated with HemoDialysis: A pilot study (BIOME-HDp).

Authors:  Mark B Lockwood; Michael J Fischer; Kimberly Silva; Blanca N Contreras; Guillermo Zamora; Amanda Goldstein; Monya Meinel; Christopher Holden; James Lash; Alana Steffens; Ardith Doorenbos
Journal:  Contemp Clin Trials Commun       Date:  2022-09-05

6.  Effects of a Novel Amino Acid Formula on Nutritional and Metabolic Status, Anemia and Myocardial Function in Thrice-Weekly Hemodialysis Patients: Results of a Six-Month Randomized Double-Blind Placebo-Controlled Pilot Study.

Authors:  Stefano Murtas; Roberto Aquilani; Gianmarco Fiori; Roberto Maestri; Paolo Iadarola; Cristina Graccione; Rita Contu; Maria Luisa Deiana; Fabrizio Macis; Romina Secci; Antonella Serra; Mariella Cadeddu; Maura D'Amato; Paola Putzu; Mirella Marongiu; Piergiorgio Bolasco
Journal:  Nutrients       Date:  2022-08-25       Impact factor: 6.706

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.